Current Investment Considerations
- Dominant position in oral delivery
- Leveraging broad technology platform for multiple product candidates
- Lead product and technology platform in Phase III
- Established leading partnerships in large and small molecule delivery
- Deep and growing product portfolio
- Flexible, low cost, easy-to-scale technology